Option chain shows key data for THE ONE ENT PCL NVDR by The One Enterprise PCL's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for THE ONE ENT PCL NVDR by The One Enterprise PCL.

THE ONE ENT PCL NVDR by The One Enterprise PCL (OTC:THDRF) Stock, Option Chain

THE ONE ENT PCL NVDR by The One Enterprise PCL

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.66 by 6.06 percent. This is a 27.27 percent increase over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $4.561 billion which beat the analyst consensus estimate of $4.424 billion by 3.09 percent. This is a 22.44 percent increase over sales of $3.725 billion the same period last year.

Earnings

Earnings Beats

News

Boston Scientific Q4 2024 Adj. EPS $0.70 Beats $0.66 Estimate, Sales $4.561B Beat $4.424B Estimate

The Offering is being conducted on a firm commitment basis. The ordinary shares are expected to commence trading on Nasdaq Capital Market under the ticker symbol "PLUT" on February 5, 2025.

IPOs

PLUT

Plutus Financial Prices IPO Of 2.10M Ordinary Shares At $4 Per Ordinary Share, For Total Gross Proceeds Of $8.4M

Citigroup analyst Filippo Falorni upgrades Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) from Sell to Neutral and raises the price target from $47 to $57.

Upgrades

Price Target

Analyst Ratings

Citigroup Upgrades Molson Coors Beverage to Neutral, Raises Price Target to $57

ZDGE

Zedge Also Expects To Benefit From The Completion (In April 2025) Of Gurushots Employee Retention Bonuses, Which Will Further Reduce Gurushots (And Zedge's) Annualized Expense Run-rate By ~$1.2M Beginning In Q4

<a href="https://www.uber.com/us/en/u/waymo-on-uber/" title="https://www.uber.com/us/en/u/waymo-on-uber/">https://www.uber.com/us/en/u/waymo-on-uber/</a>

UBER

Uber Says Waymo Coming To Uber, Launching In Austin, TX, Coming Soon To Atlanta, GA

Citigroup analyst Christopher Danely upgrades NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) from Sell to Neutral and raises the price target from $200 to $210.

NXPI

Citigroup Upgrades NXP Semiconductors to Neutral, Raises Price Target to $210

Zedge Discloses Additional Restructuring Initiatives, Mainly The Closure Of Its Norway Operations And Estimates Estimated Total Global Restructuring And Other Cost Reductions To Save $3.9M-$4.1M Annually Relative To Q1 FY25 Run Rate - FY24 Free Cash Flow Of $4.7M

Guidance

Kennametal Sees Q3 Sales Of $480M - $500M Vs. $517.58M Est; Q3 Adj EPS Of $0.20 - $0.30 Vs. $0.38 Est.

AZZ Expects FY26 Sales $1.625B - $1.725B (Est $1.681B), Adj EPS Of $5.50 - $6.10 (Est $5.82)

Kennametal Sees FY25 Sales Of $1.950B - $2.0B Vs. $2.03B; Adj EPS Of $1.05 - $1.30 Vs. $1.44 Est.

Banco Santander (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.19 by 10.53 percent. This is a 16.67 percent increase over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $17.10 billion which beat the analyst consensus estimate of $15.20 billion by 12.53 percent. This is a 9.19 percent increase over sales of $15.66 billion the same period last year.

Banco Santander Q4 GAAP EPS $0.21 Beats $0.19 Estimate, Sales $17.10B Beat $15.20B Estimate

Health Care

General

Cencora Expects 2025 Revenue Growth Of 8%-10%, From The Previous Range Of 7%-9%

Fiscal Year 2025 Expectations on an Adjusted (non-GAAP) Basis
On January 2, 2025, Cencora updated its fiscal year 2025 financial guidance only for adjusted diluted EPS following the closing of the RCA acquisition to reflect the expected contribution from RCA and momentum in the U.S. Healthcare Solutions reportable segment.
Cencora is now updating its fiscal year 2025 adjusted diluted EPS guidance to better reflect the continued momentum in the U.S. Healthcare Solutions reportable segment. Additionally, the Company is updating its fiscal year 2025 financial guidance expectations for revenue, operating income and net interest expense to reflect the impact of the RCA acquisition and the continued momentum in the U.S. Healthcare Solutions segment. The Company now expects:
<ul>
<li>Revenue growth to be in the range of 8 to 10 percent, from the previous range of 7 to 9 percent;
<ul>
<li>U.S. Healthcare Solutions revenue growth to be in the range of 9 to 11 percent, from the previous range of 7 to 9 percent;</li>
<li>International Healthcare Solutions revenue growth to be in the range of 4 to 5 percent, from the previous range of 7 to 9 percent;</li>
</ul>
</li>
<li>Adjusted diluted EPS to be in the range of $15.25 to $15.55, up from the previous range of $15.15 to $15.45 provided on January 2, 2025 and the initial guidance range of $14.80 to $15.10.</li>
</ul>
Additional expectations now include:
<ul>
<li>Adjusted consolidated operating income growth to be in the range of 11.5 to 13.5 percent, from the previous range of 5 to 6.5 percent;
<ul>
<li>U.S. Healthcare Solutions segment operating income growth to be in the range of 14.5 to 16.5 percent, from the previous range of 5 to 6.5 percent;</li>
<li>International Healthcare Solutions segment as reported operating income growth to be flat, from the previous range of 5 to 6.5 percent;
<ul>
<li>On a constant currency basis, International Healthcare Solutions segment operating income growth to be approximately 5 percent;</li>
</ul>
</li>
</ul>
</li>
<li>Net interest expense to be in the range of $290 million to $310 million, from the previous range of $150 million to $170 million; and</li>
<li>Weighted average diluted shares outstanding is expected to be under 196 million, from the previous expectation of approximately 196 million.</li>
</ul>

Cencora Expects 2025 Adjusted EPS Of 15.25-$15.55 Versus Prior Guidance Of $15.15-$15.45 And Consensus of $15.28.

RXO Sees Q1 FY25 Adj. EBITDA Of $20M-$30M, Brokerage Gross Margin Of 12%-14%

The dividend is payable March 31, 2025, to shareholders of record on March 7, 2025.

Dividends

Trane Technologies Boosts Quarterly Dividend By 12% From $0.84 To $0.94 Per Share

Needham analyst Charles Shi reiterates Ichor Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICHR#NASDAQ">ICHR</a>) from Hold to Hold.

Reiteration

ICHR

Needham Reiterates Hold on Ichor Hldgsto Hold

Kennametal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMT#NYSE">KMT</a>) reported quarterly adjusted earnings of $0.25 per share which missed the analyst consensus estimate of $0.26 by 3.85 percent. This is a 16.67 percent decrease over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $482.05 million which missed the analyst consensus estimate of $487.91 million by 1.20 percent. This is a 2.68 percent decrease over sales of $495.32 million the same period last year.

Earnings Misses

Kennametal Q2 Adj $0.25 Misses $0.26 Estimate, Sales $482.05M Miss $487.91M Estimate

RXO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) reported quarterly earnings of $0.06 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $1.667 billion which beat the analyst consensus estimate of $1.664 billion by 0.17 percent. This is a 70.45 percent increase over sales of $978.000 million the same period last year.

RXO Q4 2024 Adj. EPS $0.06, Inline, Sales $1.667B Beat $1.664B Estimate

Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) reported quarterly earnings of $3.73 per share which beat the analyst consensus estimate of $3.50 by 6.57 percent. This is a 13.72 percent increase over earnings of $3.28 per share from the same period last year. The company reported quarterly sales of $81.49 billion which beat the analyst consensus estimate of $78.38 billion by 3.96 percent. This is a 12.78 percent increase over sales of $72.25 billion the same period last year.

Cencora Q1 2025 Adj EPS $3.73 Beats $3.50 Estimate, Sales $81.49B Beat $78.38B Estimate

Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.39 by 7.69 percent. This is a 5 percent increase over earnings of $0.40 per share from the same period last year. The company reported quarterly sales of $297.03 million which beat the analyst consensus estimate of $285.98 million by 3.87 percent. This is a 8.96 percent increase over sales of $272.60 million the same period last year.

Comments

THE ONE ENT PCL NVDR by The One Enterprise PCL

THE ONE ENT PCL NVDR by The One Enterprise PCL (THDRF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga